A phase 3, double-blind, randomized, multisite trial of the efficacy, safety, and tolerability of the fixed combination torcetrapib/atorvastatin administered orally, once daily for 12 months, compared to atorvastatin alone, titrated based on NCEP [National Cholesterol Education Program] ATP [Adult Treatment Panel]-III LDL-C [low density lipoprotein cholesterol] goals in subjects with Fredrickson types IIa and IIb dyslipidemias
Latest Information Update: 05 Dec 2006
At a glance
- Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
- Indications Lipid metabolism disorders
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Dec 2006 Status change
- 25 Sep 2006 Status change
- 29 Oct 2005 New trial record.